Daily Respiratory Research Analysis
Analyzed 159 papers and selected 3 impactful papers.
Summary
The most impactful respiratory research today spans a phase 3 therapeutic trial, a large prospective diagnostic validation study, and a mechanistic multi-etiology acute lung injury atlas. Ralinepag substantially reduced clinical worsening in pulmonary arterial hypertension, while breathomics showed promise for noninvasive lung-cancer triage and integrated single-cell/spatial analyses identified etiology-specific neutrophil programs and a potential THBS1-CD36 therapeutic axis in acute lung injury.
Research Themes
- Pulmonary arterial hypertension treatment
- Noninvasive lung cancer diagnosis
- Mechanisms and therapeutic targets in acute lung injury
Selected Articles
1. Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study.
In the phase 3 ADVANCE OUTCOMES trial, 687 patients with pulmonary arterial hypertension receiving contemporary background therapy were randomized to ralinepag or placebo. A first clinical worsening event occurred in 18% of ralinepag-treated patients versus 36% receiving placebo, corresponding to a hazard ratio of 0.45, although treatment discontinuation due to adverse events was more frequent with ralinepag.
Impact: This rigorously conducted, adequately sized phase 3 trial provides high-level evidence for an oral prostacyclin-pathway option in patients already receiving modern combination therapy. The large reduction in clinical worsening may influence treatment sequencing and guideline recommendations, while the discontinuation signal requires careful patient selection and monitoring.
Clinical Implications: Ralinepag can be considered as an oral, once-daily prostacyclin-pathway treatment option for pulmonary arterial hypertension patients on background therapy. Clinicians should balance its reduction in clinical worsening against adverse effects, particularly those leading to treatment discontinuation.
Key Findings
- Among 687 analyzed patients, first clinical worsening occurred in 18% with ralinepag versus 36% with placebo.
- Ralinepag reduced the risk of first clinical worsening with a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001).
- Adverse events led to treatment discontinuation in 19% of ralinepag-treated patients versus 3% of placebo-treated patients.
Methodological Strengths
- Randomised, double-blind, placebo-controlled phase 3 design with prespecified clinical-worsening endpoint.
- Stratified randomisation, contemporary background therapy, and registration in ClinicalTrials.gov and the EU clinical-trial registry.
Limitations
- The primary endpoint was a composite outcome containing heterogeneous clinical events.
- Forty-one randomized and treated patients from sites in China were excluded because of regulatory and data-integrity concerns.
- The trial was sponsor-funded, and adverse-event-related discontinuation was substantially higher with ralinepag.
Future Directions: Further studies should define which pulmonary arterial hypertension phenotypes derive the greatest benefit, evaluate long-term survival and quality-of-life effects, and clarify optimal integration with combination therapy while minimizing treatment discontinuation.
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterised by elevated pulmonary vascular resistance that can lead to right ventricular failure and premature death. Ralinepag is an oral, once-daily, selective prostacyclin IP receptor agonist developed to treat PAH. We aimed to evaluate the efficacy and safety of ralinepag in patients with PAH. METHODS: ADVANCE OUTCOMES was a randomised, double-blind, placebo-controlled, event-driven, phase 3 trial of ralinepag in patients with PAH. Eligible patients were aged 18 years or older and PAH was diagnosed on the basis of the 2022 European Society of Cardiology and European Respiratory Society guidelines (mean pulmonary artery pressure >20 mm Hg, pulmonary artery wedge pressure ≤15 mm Hg, and pulmonary vascular resistance of >2 Wood units). Patients were randomly assigned (1:1) to ralinepag or placebo, initiated at a dose of 50 μg once daily and titrated weekly until the highest tolerated individualised dose was reached.
2. Development and Multi-center Validation of a Breathomics-Based Triage Tool for Lung Cancer: A Prospective Study of 5,214 Participants.
This prospective multicenter diagnostic study developed and externally validated a machine-learning model combining exhaled volatile organic compounds with clinical factors in 5,214 symptomatic patients with radiological lung abnormalities. The model achieved an external-validation AUC of 0.850 and 93.1% sensitivity at the prespecified rule-out threshold; in a pulmonary-medicine subgroup, the negative predictive value reached 89.0%.
Impact: The study addresses a major practical problem in lung-cancer work-up: distinguishing malignant from benign CT-detected abnormalities without immediately resorting to invasive procedures. Its large prospective design, locked model, and geographically independent validation make the findings more clinically credible than many exploratory artificial-intelligence studies.
Clinical Implications: A validated breathomics tool could eventually support outpatient triage of patients with pulmonary nodules or other radiological abnormalities, helping prioritize invasive biopsy and specialist referral. It is not yet a replacement for diagnostic imaging, tissue diagnosis, or prospective impact studies in routine clinical pathways.
Key Findings
- The study enrolled 5,214 symptomatic patients and used 4,669 participants for discovery and 545 for geographically independent external validation.
- The integrated breathomics-clinical model achieved an AUC of 0.850 in external validation.
- At the prespecified rule-out threshold, sensitivity was 93.1%; in the pulmonary-medicine subgroup, the negative predictive value was 89.0%.
Methodological Strengths
- Large prospective multicenter diagnostic-accuracy design with a geographically independent external validation cohort.
- The machine-learning model was locked before blinded external validation, reducing optimistic performance estimates.
Limitations
- Participants had radiological lung abnormalities and symptoms, so performance may not generalize to asymptomatic screening populations.
- The negative predictive value depends on disease prevalence and was lower in the overall validation cohort than in the pulmonary-medicine subgroup.
- Clinical utility, cost-effectiveness, and effects on biopsy rates or time to diagnosis were not directly demonstrated.
Future Directions: Future studies should prospectively evaluate the tool within real diagnostic pathways, assess calibration across countries and populations, test serial sampling, and determine whether its use safely reduces unnecessary biopsies without delaying cancer diagnosis.
BACKGROUND: The inherent false-positive rate of computed tomography (CT) necessitates efficient, non-invasive triage tools to distinguish lung cancer (LC) from benign mimics, thereby streamlining early detection and mitigating unnecessary invasive procedures. RESEARCH QUESTION: Can a machine learning (ML)-derived-, molecularly-resolved breathomics prediction model effectively triage patients with radiologically detected pulmonary abnormalities in a real-world symptomatic cohort? STUDY DESIGN AND METHODS: In this large-scale, prospective, multicenter diagnostic accuracy study, we enrolled 5,214 symptomatic patients with radiological lung abnormalities at two campuses. Participants were allocated into a discovery cohort (n = 4,669) and a geographically independent external validation cohort (n = 545). Exhaled volatile organic compounds (VOCs) were analyzed using high-throughput proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF-MS). An ML model integrating a specific VOCs signature with clinical factors was developed, locked, and validated blind in the external cohort.
3. Integrated single-cell and spatial transcriptomic atlas of multi-etiology acute lung injury reveals etiology-dependent neutrophil fate decisions and a prognostic neutrophil-monocyte/macrophage interaction signature.
The investigators integrated single-cell RNA sequencing of 180,031 murine lung cells across seven acute lung injury models with spatial transcriptomics. They identified 13 neutrophil subtypes organized into four macro-states, an etiology-dependent bifurcation between interferon/inflammasome and NF-κB inflammatory programs, and a prognostic 26-gene neutrophil-monocyte/macrophage interaction index; blockade of THBS1-CD36 reduced inflammatory activation and circulating neutrophils in vivo.
Impact: This work advances acute lung injury biology beyond a uniform neutrophil-centered model by resolving disease-etiology-specific immune states and spatial interactions. The experimental validation of THBS1-CD36 as a modifiable pathway provides a mechanistically grounded starting point for targeted therapy in infection- and endotoxin-driven lung injury.
Clinical Implications: The findings support etiology-specific biomarker development and suggest that THBS1-CD36 inhibition could be explored for infection- or endotoxin-associated acute lung injury. Translation requires validation in human samples and careful assessment of whether pathway blockade compromises host antimicrobial defense.
Key Findings
- Single-cell profiles from 180,031 murine lung cells across seven acute lung injury models revealed neutrophils as the most transcriptionally perturbed immune population.
- Thirteen neutrophil subtypes formed four macro-states with etiology-dependent trajectories toward interferon/inflammasome or NF-κB-driven inflammatory programs.
- A 26-gene neutrophil-monocyte/macrophage interaction index had prognostic value for sepsis mortality, and THBS1-CD36 blockade reduced inflammatory activation and circulating neutrophils in vivo.
Methodological Strengths
- Multi-etiology experimental design covering infectious, sterile, and extrapulmonary acute lung injury mechanisms.
- Integration of single-cell transcriptomics, spatial transcriptomics, pseudotime analysis, intercellular signaling, and in vivo immunobiological validation.
Limitations
- The principal atlas was generated in murine models, and species differences may limit direct translation to human acute respiratory distress syndrome.
- The prognostic interaction index and THBS1-CD36 pathway require validation in independent human cohorts and clinical samples.
- The models represent selected experimental insults and may not capture the full biological heterogeneity of intensive-care patients.
Future Directions: Future work should map these neutrophil states in human acute respiratory distress syndrome, validate the 26-gene index prospectively, determine the therapeutic window of THBS1-CD36 inhibition, and test combination strategies that preserve antimicrobial host defense.
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a life-threatening syndrome with heterogeneous etiologies and no effective pharmacological therapy. Although neutrophils are central mediators of lung injury, their functional diversity and interplay with monocyte/macrophage (Mo/MΦ) populations across etiologies remain poorly defined. Here, we integrated single-cell RNA-sequencing profiles from 180,031 murine lung cells across seven ALI models spanning infectious, sterile, and extrapulmonary insults to construct a multi-etiology neutrophil atlas. Augur identified neutrophils as the most transcriptionally perturbed immune population. Gene-set variation analysis revealed etiology-specific programs, including NF-κB/IL-6-driven inflammation in infection/sepsis, dual interferon responses in influenza, tissue-remodeling and stress-adaptive programs in bleomycin injury, and ROS-dominated injury with metabolic reprogramming after radiation.